Tag

Ozempic

All articles tagged with #ozempic

health1 day ago•57 min saved

Glp-1 weight-loss jab reverses fatty liver and eases back pain, patient credits 'food-noise' relief

A Daily Mail Health feature follows Karen Holman, who used GLP-1 medications Ozempic and then Mounjaro via telehealth weight-loss program Mosh to combat trauma-driven overeating. She shed about 12 kg in four months, and blood tests showed her fatty liver reversing with liver markers returning to normal. Now weighing roughly 58–60 kg, she reports major relief from lifelong back pain and renewed energy. Medical experts explain GLP-1 meds curb appetite by slowing stomach emptying and altering brain hunger signals, and emphasize better outcomes when combined with structured lifestyle support. The piece also notes ongoing public debate about these medications and the role of behavioral/trauma-informed care in sustainable weight loss.

via Daily Mail|

#fatty-liver #glp-1 #health

business3 days ago•2 min saved

Novo Nordisk slashes Wegovy and Ozempic prices to boost affordability

Novo Nordisk will cut Wegovy by 50% and Ozempic by 35% starting January 2027, setting a $675 per-month price for both drugs and for Rybelsus as well, as it faces competition from Lilly’s Mounjaro/Zepbound and other GLP-1 therapies; the company says the cuts aim to lower out-of-pocket costs for patients with high-deductible plans, and direct-to-patient discounts will remain unchanged.

via CBS News|

#business #glp-1 #novo-nordisk

business3 days ago•3 min saved

Novo Nordisk to cut U.S. GLP-1 drug prices by up to 50% in 2027

Novo Nordisk said U.S. list prices for Wegovy, Ozempic, and Rybelsus will be cut by up to 50% to $675 per month starting Jan. 1, 2027, targeting insured patients with high-deductible plans or co-insurance and potentially lowering out-of-pocket costs; Medicare prices will also drop to $274 per month under the Inflation Reduction Act, aiming to boost access and competition in the GLP-1 market.

via CNBC|

#business #novo-nordisk #ozempic

life-and-style9 days ago•30 min saved

Weight-loss jabs sharpen a class divide among middle-aged women

New Health Foundation data shows middle-class women aged 30–50 are the dominant private-prescription users of weight‑loss injections like Ozempic and Mounjaro, prompting debate over affordability, ethics, and long-term health effects as researchers highlight side effects and a growing class divide in obesity treatment.

via The Times|

#glp-1 #health-inequality #life-and-style

health10 days ago•3 min saved

GLP-1 Drugs Unlikely to Cause Thyroid Cancer, Review Finds

Researchers at the Clayman Thyroid Center reviewed clinical trials, adverse reports, and real-world data and found little to no evidence that GLP-1 receptor agonists (including Ozempic, Wegovy, and Mounjaro) raise the risk of thyroid cancer, including medullary thyroid cancer. Any uptick in diagnoses is likely due to detection bias from more frequent screening. While large population studies would help solidify certainty, current guidance aligns with avoiding GLP-1s only for people with personal or family histories of medullary thyroid cancer or MEN2.

via Gizmodo|

#detection-bias #glp-1 #health

health18 days ago•26 min saved

GLP-1 weight‑loss drugs may trigger nutritional gaps, doctors warn

Australian dietitians warn that GLP-1 medications (e.g., Ozempic, Wegovy, Mounjaro) can suppress appetite, but many trials didn’t monitor patients’ actual diets, potentially leading to functional malnutrition and rare deficiencies like scurvy (vitamin C) and thiamine deficiency. They’re urging dietitian‑led nutrition support alongside these drugs, while acknowledging GLP‑1s have benefits for some patients and emphasizing the need for more dietary oversight and research.

via New York Post|

#glp-1 #health #ozempic

business19 days ago•327 min saved

India set to drive down Ozempic-like drug costs as semaglutide patent nears expiry

As Novo Nordisk’s semaglutide patent nears expiry in March, Indian pharma companies are ramping up generic production of semaglutide injections (and competitors like tirzepatide), with price expectations falling from hundreds of dollars per month to about $77 initially and potentially around $40 over time. Analysts say this could trigger a global price war and transform India into a major low-cost supplier for obesity and diabetes treatments, though experts warn against misuse and stress the need for lifestyle interventions alongside medication.

via cnn.com|

#business #generics #india

health20 days ago•33 min saved

GLP-1 Weight-Loss Drugs Under Fire: Side Effects and Lawsuits Rise

An opinion piece cautions that GLP-1 medications like Ozempic, while beneficial for diabetes, can cause serious adverse effects (gastroparesis, organ issues, vision loss, muscle and bone decline) when used for vanity weight loss. It cites lawsuits against drugmakers for warnings and emphasizes the need to prioritize nutrition, metabolic health, and sustainable lifestyle changes over prolonged pharmacological use, warning against turning wellness into a perpetual drug regimen.

via dailymail.co.uk|

#glp-1 #health #lawsuits

healthcare21 days ago•10 min saved

MHRA warns Ozempic/Wegovy could cause rare eye condition

Britain's MHRA has warned that the diabetes/weight‑loss injections Ozempic (semaglutide) and Wegovy may cause a rare optic nerve condition (NAION) that can lead to sudden vision loss in one eye. The regulator has received three reports, but says the overall risk is very small; with about two million UK users, patients and clinicians are advised to be alert to symptoms and seek urgent eye care if vision changes occur. The warning also notes that pancreatitis is a known but infrequent side effect of GLP-1 weight‑loss drugs.

via The Times|

#healthcare #mhra #naion

health21 days ago•56 min saved

Gluten-free reboot: shedding two dress sizes in three months without injections

A UK woman details how, after a family challenge to give up bread, she lost about two stone (from a size 18 to 10) in three months by cutting out gluten, sugar and alcohol and focusing on foods that naturally stimulate GLP-1 (eggs, fish, legumes, vegetables, olive oil, nuts). She credits a healthier lifestyle with reversing prediabetes, more energy, and better mood, while noting that weight-loss jabs (like Ozempic/Mounjaro/Wegovy) can have side effects and often lead to rebound weight after stopping. She emphasizes sustainability, daily exercise, and choosing nutrient-dense, high-satiety foods over processed carbs as an alternative to injections.

via dailymail.co.uk|

#glp-1 #gluten-free #health

business23 days ago•4 min saved

Novo Nordisk Braces for 2026 as Weight-Loss Drug Rivalry Intensifies

Novo Nordisk warned that 2026 sales could fall as much as 13% due to fierce competition from Eli Lilly’s weight-loss drugs and government pricing pressure, marking the first annual decline since Ozempic’s launch; Lilly projected continued growth. The company also reported strong early uptake for a pill version of Wegovy and is pursuing a higher 7.2 mg dose, even as leadership shakeups and patent expirations keep the turnaround challenging and sent Novo's shares lower.

via The New York Times|

#business #lilly #novo-nordisk

business23 days ago•3 min saved

Painful price cuts push Novo Nordisk shares lower amid Wegovy pressure

Novo Nordisk warned profits and sales could fall as much as 13% due to unprecedented price pressure on GLP-1 weight‑loss drugs, amplified by a U.S. government price deal. The news sparked an about 18% drop in the stock as the company grapples with competition from Eli Lilly, patent expiries, and ongoing cost-cutting, with CEO Maziar Doustdar saying the cuts are painful but intended to broaden access and drive future growth.

via BBC|

#business #novo-nordisk #ozempic

business24 days ago•2 min saved

Novo Nordisk Slips on 2026 Sales Outlook Amid Ozempic/Wegovy Pressure

Novo Nordisk beat 2025 sales estimates but warned that 2026 sales will fall 5%–13% at constant exchange rates, reversing last year’s growth. The drop is driven by expected weaker U.S. sales amid competition from Lilly’s tirzepatide and pricing pressures under MFN reforms, even as international sales may rise with Wegovy expanding into more markets. The outlook sent the stock lower, with U.S.-listed shares sliding about 14% after the report.

via Barron's|

#2026-sales-decline #business #novo-nordisk

business24 days ago•3 min saved

Novo Nordisk stock slides on 2026 outlook amid pricing headwinds and exclusivity losses

Novo Nordisk warned that 2026 sales and operating profit could fall 5%–13% at constant exchange rates due to U.S. pricing pressure and loss of exclusivity for Wegovy and Ozempic in markets like Canada, Brazil and China, sending its shares down as much as 14% after a trading halt. The company cited continued price pressure and intensified competition from Lilly’s weight‑loss drugs, even as it rolled out an oral Wegovy in the U.S. and pursued next‑generation GLP‑1 products. In Q4, net sales were 79.1 billion Danish kroner with Ozempic at 31.8 billion and Wegovy at 21.9 billion, while 2025 saw sales up 10% and operating profit up 6%. Investors are watching for potential U.S. volume gains and how pricing deals and competition will affect 2026 guidance.

via CNBC|

#business #competition #glp-1

health1 month ago•23 min saved

Stopping Ozempic and Wegovy Typically Reverses Weight Loss Within 1.5 Years

A Wall Street Journal piece explains that GLP-1 weight-loss medications like Ozempic and Wegovy are intended as lifelong treatments for obesity, not quick lifestyle fixes; studies show most people who stop the drugs regain the lost weight within about 1.5 years, underscoring the need for ongoing treatment and monitoring.

via The Wall Street Journal|

#glp-1-weight-loss-drugs #health #obesity-treatment